A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rui Zhang, MD, Prof
Beijing Children's Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Swedish Orphan Biovitrum Research Site
Shanghai, Fudan, China
- Swedish Orphan Biovitrum Research Site
Beijing, Xicheng, China
- Swedish Orphan Biovitrum Research Site
Beijing, China
- Swedish Orphan Biovitrum Research Site
Chongqing, China
- Swedish Orphan Biovitrum Research Site
Guangzhou, China
- Swedish Orphan Biovitrum Research Site
Nanjing, China
- Swedish Orphan Biovitrum Research Site
Zhengzhou, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Feb 2023
- Primary completion
- 21 Feb 2025
- Completion
- 8 Aug 2025
- Last update posted
- 13 Mar 2026
- Registered enrollment
- 13
- Registry id
- NCT05744063
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.